Richard P. Junghans
Associate Professor of Surgery and Medicine
Education:
MD, University of Miami
PhD, University of California, Berkley
General field of research:
Immunology; Oncology; Gene Therapy
Affiliations other than medicine:
Evans Center for Interdisciplinary Biomedical Research
Roger Williams Medical Center Chief, Division of Surgical Research Department of Surgery
Contact information:
Office
825 Chalkstone Avenue Providence, RI 02908
Keywords:
T cells Immunotherapy; Gene Therapy
Summary of research interest:
Richard P. Junghans, Ph.D., M.D., Associate Professor of Surgery and Medicine, Boston University School of Medicine, is Chief, Division of Surgical Research, Department of Surgery; Director, Biotherapeutics Development Lab (BDL). Dr. Junghans brings dual backgrounds in basic science and clinical medicine to a research program in clinical translational research. He obtained his MD (U Miami) and training in Internal Medicine (Georgetown) and Hematology-Oncology (NCI/NIH), where he trained in immunology with Dr Thomas Waldmann, and his Ph.D. in Molecular Biology (UC Berkeley) in which his thesis described activities of retrovirus reverse transcriptases.
He applies molecular engineering techniques to develop new immunotherapies to treat cancer and infectious diseases, and is a rec0gnized leader in the field of cancer gene therapy. He has completed Institutional Review Board applications, initiated Phase I and Phase II human clinical trials, secured FDA Investigational New Drug (IND) status for antibody and gene therapy agents and previously established an on-campus facility for gene therapy applications. Dr. Junghans has more than 70 publications. He is Board Certified in Internal Medicine and Medical Oncology and Board Eligible in Hematology.
Recent publications:
Koon HB, Severy P, Hagg DS, Butler K, Hill T, Jones AG, Waldman TA, Junghans RP. 2006. Antileukemic effect of daclizumab in CD25 high-expressing leukemias and impact of tumor burden on antibody dosing. Leuk Res; 30:190-203.
Scheinberg DA, Mulford DA, Jurcic JG, Sgouros G, Junghans RP. Antibody therapies of cancer. 2006. In Chabner BA, Longo DL (ed), Cancer Chemotherapy and Biotherapy: Principles and Practice. Lippincott, Wheeler and Wilkins, Philadelphia; 666-98.
Wang Y, Ylera F, Kang S-G, Kutok JL, Klein-Szanto AJP, Junghans RP. Focused antibody response in plasma cell-infiltrated non-medullary (NOS) breast cancers. 2007. Breast Cancer Res Treat; 104:129-44.
Yang W, Beaudoin E, Lu L, Du Pasquier RA, Kuroda MJ, Willemsen R, Koralnik IJ, Junghans RP. 2007. Chimeric immune receptors specific to JC virus for immunotherapy of progressive multifocal leukoencephalopathy. Int Immunol; 19:1083-93.
Beaudoin EL, Bais AJ, Junghans RP. Sorting vector producer cells for high transgene expression increases retroviral titer. 2008. J Virological Methods; 148:253-9.
Junghans RP. 2008. Dystrophia myotonia: An unfitting focus on foci? Eur J Human Genet; in press.
Emtage PCR, Lo ASY, Liu DL, Gomes EM, Gonzalo-Daganzo R, Junghans RP. 2008. 2nd generation anti-CEA designer T cells resist activation-induced cell death, proliferate on tumor contact, secrete cytokines and exhibit superior anti-tumor activity in vivo: a preclinical evaluation. Clin Cancer Res; in second review.
Technologies available for sharing upon request:
Immunology therapy protocols; Gene Transfer protocols; Investigation New drug filing with FDA Clinical protocol development and implementation
Dept. of Medicine Podcasts
- Amyloid Program on NPR’s All Things Considered May 21, 2012
- Creating an Inclusive Working Environment May 7, 2012
- Turning Quality Improvement Projects into Scholarship February 14, 2012
